Pivotal's public equity team invests in publicly listed companies with innovative therapeutics, devices, or biomedical tools that are underappreciated by the market. We invest globally and primarily in the small- to mid-cap space. We leverage deep fundamental research and rigorous financial analysis to help select potentially undervalued companies, with a focus on opportunities with specific catalysts, in order to achieve attractive long-term risk adjusted returns.